NCT04258943 2025-09-18Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid LeukemiaChildren's Oncology GroupPhase 1/2 Active not recruiting60 enrolled 1 FDA